TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. This is a free site for all.
Thank you.


Monday, May 8, 2017

FoxFeed Blog Palfreman: Toward Parkinson's Personalized Medicine

In his latest blog post for the Journal of Parkinson's Disease, science journalist and person with Parkinson's Jon Palfreman introduces us to Personalized Parkinson Project. This Netherlands study aims to understand the variability of this disease to develop and recommend treatments based on an individual's profile.
"My dream is to end up with a decision support system, a black box, that sits on the clinician's desk. And now he can say, 'based on your kinetic profile, your CSF result, your stool analysis ... the best evidence suggests that people like you do well when they get this particular treatment," principal investigator Bastiaan Bloem, MD, PhD -- professor of Neurological Movement Disorders at Radboud University Nijmegen Medical Centre in the Netherlands and founder of ParkinsonNet, a network of Parkinson's care providers -- tells Palfreman.
The study is modeled after the MJFF-led Parkinson's Progression Markers Initiative and will, like PPMI, make its data accessible to the broad research community.
"We know that findings from any study gain value if they can be replicated and found consistent across different populations," says MJFF CEO Todd Sherer, PhD. "Having two studies modeled in a similar fashion dramatically accelerates the speed we can validate and actionize insights."

https://www.michaeljfox.org/foundation/news-detail.php?palfreman-toward-parkinson-personalized-medicine

No comments:

Post a Comment